arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

Park Ha Biological Technology Co., Ltd.

BYAH

$2.62 ▲ +0.06 (+2.35%) at close

5 Visible periods

27 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Park Ha Biological Technology Co., Ltd. shows weak fundamentals, weighed down by Return on Invested Capital and FCF Margin (%). These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $1.5M

Dividend Yield —

Revenue Growth 6.0% ↗

Op. Margin None

ROIC -611.5% ↘

FCF / Share $0.15 ↗

Trailing P/E —

Price / Book 0.4x

FCF Yield 5.6%

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.52M

↑ +6.0% —

Net Income Profit after all expenses

$-24.36M

↓ -5191.3% —

Operating Margin Operating profit as % of sales

33.3%

↓ -30.6% —

FCF / Share Free cash flow per share

$0.15

↑ +279.5% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -611.5% is weak on an absolute basis (target > 10%)
FCF Margin (%)FCF Margin (%) of 3.4% is weak on an absolute basis (target > 10%)
FCF / Net IncomeFCF / Net Income of -0.00x is weak on an absolute basis (target > 1x)

Health Breakdown

Profitability ↓

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Oct 31, 2025 20-F ↗	FY 2024 Oct 31, 2024 20-F ↗	FY 2023 Oct 31, 2023 20-F ↗	FY 2022 Oct 31, 2022 20-F ↗	FY 2021 Oct 31, 2021 20-F ↗
Revenue Growth YoY (%)	6.0% Fair ↓ Fair Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+50%)	-3.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-179%)	28.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+603%)	—	—
EPS Growth YoY (%)	N/M	-33.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	200.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	N/M	-43.8% Weak Weak Year-over-year change in net income	345.4% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	279.5% Excellent → Excellent Stable Year-over-year change in free cash flow	659.0% Excellent Excellent Year-over-year change in free cash flow	-91.2% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	9.6% Fair Fair Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Oct 31, 2025 20-F ↗	FY 2024 Oct 31, 2024 20-F ↗	FY 2023 Oct 31, 2023 20-F ↗	FY 2022 Oct 31, 2022 20-F ↗	FY 2021 Oct 31, 2021 20-F ↗
Operating Margin (%) (%)	—	33.3% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+122%)	48.0% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+220%)	10.3% Caution Caution Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-32%)	—
Effective Tax Rate (%) (%)	-1.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	39.7% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	27.9% Caution Caution Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	20.1% Excellent ↓ Excellent Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+101%)	34.6% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+246%)	10.0% Caution Caution Net income as a percentage of revenue Optimal: > 15% vs Sector: At sector avg	—
FCF Margin (%) (%)	3.4% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	40.3% Excellent → Excellent Stable Free cash flow as a percentage of revenue Optimal: > 10%	5.1% Caution Caution Free cash flow as a percentage of revenue Optimal: > 10%	75.1% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	-0.00x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	2.01x Excellent ↓ Excellent Declining Free cash flow relative to reported net income Optimal: > 1x	0.15x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	7.54x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Oct 31, 2025 20-F ↗	FY 2024 Oct 31, 2024 20-F ↗	FY 2023 Oct 31, 2023 20-F ↗	FY 2022 Oct 31, 2022 20-F ↗	FY 2021 Oct 31, 2021 20-F ↗
Return on Invested Capital (%)	-611.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	31.8% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	84.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	132.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-405.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	25.7% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	52.1% Excellent Excellent Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	—	31.8% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+27%)	84.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+237%)	127.3% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+409%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Oct 31, 2025 20-F ↗	FY 2024 Oct 31, 2024 20-F ↗	FY 2023 Oct 31, 2023 20-F ↗	FY 2022 Oct 31, 2022 20-F ↗	FY 2021 Oct 31, 2021 20-F ↗
Interest Coverage (x)	—	—	—	1015.59x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-3.79M	$-547.50K	$-1.03M	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Oct 31, 2025 20-F ↗	FY 2024 Oct 31, 2024 20-F ↗	FY 2023 Oct 31, 2023 20-F ↗	FY 2022 Oct 31, 2022 20-F ↗	FY 2021 Oct 31, 2021 20-F ↗
Revenue per Share (USD)	$4.29	$0.10	$0.10	$0.08	—
Basic EPS, GAAP (USD)	$-41.38	$0.02	$0.03	$0.01	—
Free Cash Flow per Share (USD)	$0.15	$0.04	$0.01	$0.06	—
Book Value per Share (USD)	$6.78	$0.06	$0.04	$0.01	—
Tangible Book Value per Share (USD)	$6.77	$0.06	$0.04	$0.01	—
Basic Weighted Avg Shares (shares)	588,866	25.00M	25.00M	25.00M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Oct 31, 2025 20-F ↗	FY 2024 Oct 31, 2024 20-F ↗	FY 2023 Oct 31, 2023 20-F ↗	FY 2022 Oct 31, 2022 20-F ↗	FY 2021 Oct 31, 2021 20-F ↗
Working Capital (USD)	$3.62M	$1.32M	$933.24K	—	—
Total Equity (USD)	$3.99M	$1.51M	$1.01M	$150.28K	$-578.18K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Oct 31, 2025 20-F ↗	FY 2024 Oct 31, 2024 20-F ↗	FY 2023 Oct 31, 2023 20-F ↗	FY 2022 Oct 31, 2022 20-F ↗	FY 2021 Oct 31, 2021 20-F ↗
Sales/Revenue/Turnover (USD)	$2.52M	$2.38M	$2.46M	$1.92M	—
Depreciation Expense (USD)	$108.40K	$21.71K	$19.07K	—	—
Net Income, GAAP (USD)	$-24.36M	$478.56K	$852.04K	$191.30K	—
Operating Cash Flow (USD)	$85.85K	$960.47K	$126.54K	$1.44M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 5 years · 5 quarters

Park Ha Biological Technology Co., Ltd.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare BYAH with peers